Hookipa Update on Business Priorities and Oncology Partnership Programs

 

• HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease
   
• HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milestone payment associated with submission of Investigational New Drug application
   
• HOOKIPA will implement cost saving initiatives, including a reduction of workforce by approximately 30 percent
   
• HOOKIPA maintains a strong cash position of $117.5 million as of December 31, 20231

https://www.globenewswire.com/news-release/2024/01/29/2818871/0/en/HOOKIPA-Pharma-Provides-Update-on-Business-Priorities-and-Oncology-Partnership-Programs.html